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High-dose atorvastatin in peripheral arterial disease (PAD):
effect on endothelial function, intima-media-thickness and local
progression of PAD. An open randomized controlled pilot trial
Abstract
Beneficial effects of aggressive lipid-lowering with high-dose atorvastatin (80 mg/day) have been
demonstrated in patients with coronary and cerebrovascular disease. The impact of such a therapy in
patients with peripheral arterial disease (PAD) is less known so far. Here we studied the effects of
high-dose atorvastatin on brachial artery endothelial function, common carotid intima-media thickness
(IMT) and local progression of PAD in these patients. One hundred of 500 patients screened with
documented PAD were randomly assigned to receive 80 mg of atorvastatin daily for six months or to
continue on conventional medical treatment. Ninety-six percent of patients in the control group were on
standard statin treatment. High resolution B-mode ultrasonography was used to study brachial artery
flow-mediated dilation (FMD), IMT and ankle-brachial index (ABI) at baseline and at six months. FMD
and IMT at baseline and at six months were 4.1 (0.06-8.6) versus 5.0 (0.76 vs. 8.1) %, p = 0.96, and 0.76
(0.66-0.82) versus 0.73 (0.63-0.81) mm, p = 0.41, respectively, in the atorvastatin group, and 2.66
(-1.9-6.9) versus 3.65 (0.0-8.6)%, p = 0.02, and 0.78 (0.71-0.90) versus 0.77 (0.70-0.90) mm, p = 0.48,
in the control group. ABI at baseline and at six months was not different in either group. LDL
cholesterol was reduced from 2.53 (2.21-3.28) to 1.86 (1.38-2.29) mM (p < 0.0001) in the atorvastatin
group, whereas levels remained stable in the control group [2.38 (1.94-3.16) vs. 2.33 (1.82-2.84) mM, p
= 0.61]. Major adverse cardiovascular events occurred in 2.1% in the atorvastatin group and 1.9% in the
control group (p = 0.61). In conclusion, in this pilot trial aggressive lipid-lowering with 80 mg of
atorvastatin daily for six months had no effect on brachial artery FMD in patients with PAD. IMT and
ABI were also similar in patients with and without high-dose atorvastatin at six months.
© 2008 Schattauer GmbH, Stuttgart
182
High-dose atorvastatin in peripheral arterial disease (PAD):
Effect on endothelial function, intima-media-thickness and local
progression of PAD
An open randomized controlled pilot trial
Silviana Spring
1
, Roger Simon
1
, Bernd van der Loo
1
, Tamara Kovacevic
1
, Christiane Brockes
1
, Valentin Rousson
2
,
Beatrice Amann-Vesti
1
, Renate Koppensteiner
1
1
Clinic of Angiology, Department of Medicine, University Hospital Zurich, Switzerland;
2
Department of Biostatistics, ISPM, University Zurich,
Zurich, Switzerland
Summary
Beneficial effects of aggressive lipid-lowering with high-dose
atorvastatin (80 mg/day) have been demonstrated in patients
with coronary and cerebrovascular disease.The impact of such
a therapy in patients with peripheral arterial disease (PAD) is
less known so far.Here we studied the effects of high-dose ator-
vastatin on brachial artery endothelial function, common caro-
tid intima-media thickness (IMT) and local progression of PAD in
these patients. One hundred of 500 patients screened with
documented PAD were randomly assigned to receive 80 mg of
atorvastatin daily for six months or to continue on conventional
medical treatment.Ninety-six percent of patients in the control
group were on standard statin treatment. High resolution
B-mode ultrasonography was used to study brachial artery flow-
mediated dilation (FMD), IMT and ankle-brachial index (ABI) at
baseline and at six months. FMD and IMT at baseline and at six
months were 4.1 (0.06–8.6) versus 5.0 (0.76 vs. 8.1) %, p=0.96,
Keywords
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and 0.76 (0.66–0.82) versus 0.73 (0.63–0.81) mm, p=0.41, re-
spectively, in the atorvastatin group, and 2.66 (-1.9 – 6.9) versus
3.65 (0.0–8.6)%, p=0.02, and 0.78 (0.71–0.90) versus 0.77
(0.70–0.90) mm,p=0.48, in the control group.ABI at baseline and
at six months was not different in either group. LDL cholesterol
was reduced from 2.53 (2.21–3.28) to 1.86 (1.38–2.29) mM
(p<0.0001) in the atorvastatin group, whereas levels remained
stable in the control group [2.38 (1.94–3.16) vs.2.33 (1.82–2.84)
mM, p=0.61]. Major adverse cardiovascular events occurred in
2.1% in the atorvastatin group and 1.9% in the control group (p=
0.61). In conclusion, in this pilot trial aggressive lipid-lowering
with 80 mg of atorvastatin daily for six months had no effect on
brachial artery FMD in patients with PAD.IMT andABI were also
similar in patients with and without high-dose atorvastatin at six
months.
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Introduction
Beneficial effects of an aggressive lipid-lowering therapy with
high-dose atorvastatin (80 mg/day) have previously been dem-
onstrated in patients with coronary heart disease. In the MIR-
ACLE Study this therapy reduced the frequency of recurrent
ischemic cardiovascular events in patients with acute coronary
syndromes within the first 16 weeks (1). Furthermore, intense
statin therapy has been shown to have an effect both in the pri-
mary (2) and secondary prevention of stroke (3).
The effects of an aggressive lipid-lowering therapy in pa-
tients with peripheral arterial disease (PAD) have not been exten-
sively investigated so far. Although cardiovascular morbidity
and mortality are increased in patients with PAD, with myo-
cardial infarction and stroke being the main causes of death (4,
5), there are, to date, only little data concerning these effects on
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the local progression of PAD and on major adverse cardiovascu-
lar events (MACE) in this patient group.
The mechanisms by which statins may achieve those effects
involve, apart from and independent of their lipid-lowering prop-
erties, pleiotropic effects (6) such as the improvement of en-
dothelial function (7), modulation of inflammation (8), reduc-
tion of common carotid intima-media thickness (IMT) (9), and
reduction of oxidative stress (10).
Endothelial dysfunction, assessed non-invasively by brachial
artery flow-mediated dilation (FMD), represents an early precur-
sor of atherosclerosis. Both in patients with cardiovascular risk
factors and in patients with either ischemic heart disease or PAD
FMD has been shown to be reduced (11–14). Furthermore, it is
an independent predictor of cardiovascular risk in patients with
PAD (15, 16). IMT is also known as an established indicator for
early generalized atherosclerosis (17, 18) and has been demon-
strated to be a strong predictor for both cardiovascular and cer-
ebrovascular events (19, 20). Changes in IMT can easily be vis-
ualized by B-mode ultrasonography (21) which is commonly
used in interventional studies of lipid-lowering therapies.
Therefore, we wanted to test the hypothesis that, in patients
with PAD, intense lipid-lowering therapy with high-dose ator-
vastatin (80 mg/day), administered over a period of six months,
would improve FMD. In addition, effects on IMT, local progres-
sion of PAD and the occurrence of MACE were recorded up to
six months.
Methods
Study design
This open, prospective single-center trial had a parallel group de-
sign in which patients were randomized to one of two treatment
arms. Group 1 received, in addition to the current medication,
80 mg atorvastatin per day for six months.Any other lipid-lower-
ing drug in group 1 was discontinued and replaced by high-dose
atorvastatin without washout period. Group 2 (controls) received
standard statin treatment according to the National Cholesterol
Education Program (NCEP) guidelines (22). LDL cholesterol
level was targeted to levels < 100 mg/dl.
The randomization code was developed using a computer
random number generator to select random permuted blocks.
Patients
Patients with angiographically or sonographically documented
PAD of the lower extremities, with or without a history of periph-
eral vascular intervention or vascular surgery, were eligible and
were consecutively recruited from PAD patients who had regular
consultation at our clinic of angiology.The severity of PAD at the
time of enrollment was classified according to Rutherford. Only
patients with Rutherford category 0 to 3 (corresponding to Fon-
taine stages I and II) were eligible.
Exclusion criteria were non-atherosclerotic vascular disease,
pregnancy, life expectancy < six months, active liver disease (cir-
rhosis, hepatitis), and known intolerance against atorvastatin.
The study protocol was approved by the local ethics commit-
tee, and all patients gave written informed consent.
At baseline patients’age, sex, current medication and vascular
risk factors (diabetes, defined as fasting serum glucose
≥7 mM or use of oral antidiabetics or insulin; hyperlipidemia, de-
fined as use of lipid-lowering drugs or total cholesterol >5.17 mM
and/or triglycerides >2.26 mM; hypertension, defined as systolic
blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg;
current smoking) were recorded. The patients were asked about
manifestations of coronary heart disease (prior angina, acute cor-
onary syndromes, myocardial infarction, percutaneous coronary
intervention, aorto-coronary bypass graft) and cerebrovascular
events (prior transient ischemic attack, stroke, carotis stenting or
carotid endarterectomy). Furthermore, a careful clinical examin-
ation was done including palpation of peripheral pulses and aus-
cultation of bruits. Non-invasive pulse volume recordings and
ankle systolic pressure measurements for calculation of the ankle-
brachial index (ABI) at rest were performed, too.
Laboratory analyses
The following laboratory measurements were done by using es-
tablished standard methods: liver function tests, creatine kinase
(CK), C-reactive protein (CRP), D-dimer, fibrinogen, blood glu-
cose, total cholesterol, HDL-cholesterol, LDL-cholesterol, trig-
lycerides and lipoprotein a.
Carotid and brachial artery ultrasound
FMD of the brachial artery and IMT of the common carotid ar-
tery (CCA) were determined by high-resolution B-Mode ultra-
sound.
Measurements of FMD were done according to Celermajer et
al. (11). In brief, FMD was assessed on the right brachial artery
with the use of a 7.5-MHz linear transducer after the patients lay
quietly for 10 minutes (min). We scanned the brachial artery in
longitudinal section 2–15 cm above the elbow. The clearest picture
of the anterior and posterior intimal layers was obtained, the skin
was marked at the position of the transducer which was kept like
that throughout the study.The diameter and the peak velocity of the
brachial artery at rest and during reactive hyperemia was
measured; reactive hyperemia was induced by a pneumatic cuff,
placed around the forearm, being inflated to 250 mmHg for 4.5
min, and then released. After recovery of the vessel for 10– 15 min
and 4 min after subsequent sublingual administration of nitro-
glycerin 0.8 mg, the diameter and peak systolic velocity were deter-
mined again to assess endothelium-independent vessel reaction.
To assess IMT, a 7.5 MHz linear transducer was used to
measure the distance between two echogenic zones that cor-
respond to the boundaries between lumen/intima and media/ad-
ventitia. According to the meta-analysis by Kanters et al. (23)
combined measurements of the near and far wall might enhance
precision without loss of validity. Furthermore, variability of
IMT measurements is lowest when determining the mean thick-
ness in more than one direction (23). Therefore, IMT was de-
fined as the mean of a total of 24 measurements of the near and
far wall on both the left and right CCA recorded from an antero-
lateral, mediolateral and posterolateral position. All measure-
ments were taken 1.5 – 2 cm proximal to the bifurcation and were
ECG-triggered (on the R-wave). Measurements were always
done by the same experienced ultrasonographer who was blinded
to treatment assignment for the duration of the study.
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Follow-up and endpoints
In the atorvastatin group liver function tests as well as measure-
ment of the CK were done at 2, 6, and 12 weeks, and the patients
were asked about the occurrence of side effects (myalgia, consti-
pation, flatulence, diarrhea, abdominal pain, nausea, dyspepsia,
headache, insomnia) of the atorvastatin therapy.
At six months, FMD, IMT, ABI and routine laboratory
measurements were done in both groups. Furthermore, a history
was taken with special regard to the symptoms of PAD and the oc-
currence of vascular events during follow up, and a clinical exam-
ination (palpation of pulses, auscultation of bruits) as well as non-
invasive pulse volume recordings and ABI measurements at rest
were performed. Progression of PAD was defined as drop in ABI
by ≥0.1 with or without worsening of clinical symptoms. The oc-
currence of MACE (defined as non-fatal myocardial infarction,
coronary revascularization, coronary death, non-fatal or fatal
stroke or any vascular death) was also recorded at six months.
The primary endpoint was brachial artery FMD at six
months. IMT at six months was a secondary endpoint.
Sample size calculation and statistical analysis
A sample size of 47 patients per group was calculated to detect a
40% difference in FMD between the two treatment groups with
80% power and significance at the 5% level (two sided). To com-
pensate for drop outs, an overall of 100 patients were included in
the study.
Statistical analysis was perfomed using Statview 5.0. All ana-
lyses were performed on an intention-to-treat basis and involved
all patients who were randomly assigned. Continuous variables
were summarized as medians and interquartile range and categori-
cal variables as counts and percentages. Comparison between the
two treatment groups were done using a Mann-Whitney test for
continuous variables and using a chi-square test or a Fisher's exact
test for categorical variables. For the main enpoints of the study
(FMD, IMT and ABI at 6 months), which were approximately
normally distributed as checked using boxplots, a multivariate
analysis has been carried out with the measurement at six months
as the response, the treatment group as factor and the baseline
values and age as covariates in a multiple regression model. This
allowed us to compare both treatment groups at six months for in-
dividuals having the same baseline value and the same age. This
also allowed us to adjust for the slight age and baseline imbalances
between the groups in spite of the randomisation. P-values lower
than 0.05 were considered as statistically significant.
Figure 1: Flow of participants throughout
the study.
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Results
Of 500 patients screened, 103 did not meet the entry criteria, 200
refused to participate, 33 were excluded because of liver disease
(increase in liver function tests, known cirrhosis or hepatits), 17
because of life expectancy < six months, 25 because of known in-
tolerance against atorvastatin and 22 because of non-athero-
sclerotic vascular disease.
Of the 100 patients enrolled (78 men, 22 women), 48 patients
were randomized to high-dose atorvastatin and 52 to conven-
tional medical treatment.The flow of the participants throughout
the study is shown in Figure 1.
One patient in the control group was lost to follow-up. Three
patients in the atorvastatin group discontinued the drug because
of clinical symptoms (diarrhea N=1, abdominal pain N=1, obsti-
pation N=1), and one because of excessive alcohol consumption;
five patients developed elevated liver enzymes (N=3; 2 patients
with ALT > 3x upper limit of normal) or elevated CK (N=2, CK
> 10x upper limit of normal).
One patient developed a cerebral tumor, and therefore his
study participation was terminated by the investigators.
In Table 1 baseline characteristics by treatment group are
shown. Patients in the atorvastatin group were slightly younger
than those in the control group, but there were no differences be-
tween the groups with respect to vascular risk factors, lipid
status, concomitant medication and severity of PAD (Rutherford
classification, ABI).
In the control group, 50 patients (96.1%) were on long-term
statin therapy during the initial visit. The following statins were
used: simvastatin 10 mg in one patient (1.9%), 20 mg in six pa-
tients (11.5%) and 40 mg in two patients (3.8%); pravastatin 10
mg in two patients (3.8%), 20 mg in six patients (11.5%) and 40
mg in seven patients (13.5%); atorvastatin 10 mg in two patients
(3.8%), 20 mg in 18 patients (34.6%) and 40 mg in three patients
(5.8%); fluvastatin 20 mg in one patient (1.9%), and rosuvastatin
20 mg in one patient (1.9%). In two patients statin therapy was
initiated.
FMD
FMD of the brachial artery was not significantly different be-
tween the groups at baseline [atorvastatin vs. control group: 4.1
(0.1–8.6) vs. 2.7 (-1.9–6.9)%, p=0.18] and at six months [5.0
(0.8–8.1) vs. 3.7 (0.0–8.6)%, p=0.74] (Fig. 2). In the multivariate
analysis, FMD at six months was on average 1.4% lower for the
atorvastatin group compared to the control group (adjusted for
baseline FMD and age), this difference being not significant
(p=0.44).
IMT
IMT was significantly lower in the atorvastatin group than in the
control group at baseline [0.76 (0.66=0.82) vs. 0.78 (0.71–0.90)
mm, p=0.046] and at six months [0.73 (0.63–0.81) vs. 0.77
(0.70–0.90) mm, p=0.031] (Fig. 3). But in the multivariate analy-
sis, IMT at six months was on average only 0.01 mm lower for the
atorvastatin group compared to the control group (adjusted for
baseline IMT and age), this difference being no longer signifi-
cant (p=0.58).
Patients with and without progression of the IMT during fol-
low-up, expressed as % change from baseline, were similar in the
atorvastatin group and in the control group (Fig. 3B).
Table 1: Baseline characteristics of the patients by group.
Atorvastatin
(N=48)
Control (N= 52) P
Age, years 063 (58–72) 071 (63–78) 0.0033
Gender (male) 040 (83.3%) 038 (73.1%) 0.22
2 008 (16.6%) 006 (11.5%)
3 008 (16.6%) 007 (13.5%)
Ankle-brachial index
(ABI)
000.84 (0.69–1.00) 000.90 (0.70–1.00) 0.74
Coronary heart
disease
018 (37.5%) 022 (42.2%) 0.62
history of ischemic
stroke or TIA
008 (16.7%) 015 (28.8%) 0.15
Aspirin 030 (62.5%) 033 (63.5%) 0.92
Clopidogrel 005 (10.4%) 004 (7.7%) 0.63
Aspirin and
clopidogrel
006 (12.5%) 010 (19.2%) 0.36
ACE inhibitor 009 (18.8%) 016 (30.8%) 0.17
Beta-blocker 016 (33.3%) 027 (51.9%) 0.06
Angiotensin II
receptor antagonist
017 (35.4%) 018 (34.6%) 0.93
Vitamin K antagonist 010 (20.8%) 009 (17.3%) 0.65
BMI, kg/m
2
025.2 (23.3–27.3) 025.5 (23.9–27.5) 0.52
Smokers 017 (35.4%) 015 (28.8%) 0.48
Pack years, years 040 (20–56) 035 (12.5–50) 0.39
Diabetes mellitus 013 (27.1%) 016 (30.8%) 0.68
Blood glucose, mM 005.35 (4.7–6.0) 005.10 (4.67–6.10) 0.54
Arterial hypertension 035 (72.9%) 042 (80.8%) 0.35
Systolic BP, mmHg 140 (130–150) 142.5 (132.5–155) 0.29
Diastolic BP, mmHg 080 (70–85) 080 (70–85) 0.99
Hypercholesterolemia 034 (70.8%) 040 (76.9%) 0.49
Total cholesterol, mM 004.70 (4.30–5.20) 004.50 (4.10–5.00) 0.24
LDL cholesterol, mM 002.53 (2.21–3.28) 002.38 (1.94–3.16) 0.16
HDL cholesterol, mM 001.25 (1.01–1.54) 001.19 (0.99–1.43) 0.32
Triglycerides, mmol/l 001.67 (1.18–2.52) 001.88 (1.28–2.44) 0.64
Lipoprotein a, mg/l 166.5 (57–446.5) 166 (47–578.5) 0.68
CRP, mg/l 003.00 (1.50–7.3) 003.4 (1.65–5.50) 0.88
Fibrinogen, mg/dl 350 (325–403.75) 357.50 (325–415) 0.51
D-Dimer, mg/l 000.20 (0.20–0.40) 000.35 (0.20–0.60) 0.0054
history of peripheral
vascular intervention/
surgery
037 (77%) 042 (80%) 0.83
Rutherford classification
0 025 (52%) 031 (59.6%) 0.46
1 007 (14.5%) 008 (15.3%)
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ABI and reintervention
ABI was not different between the groups at baseline (Table 1;
Fig. 4) and at six months [0.89 (0.70–1.10) vs. 0.90
(0.77–1.00)%, p=0.79] (Fig. 4). In the multivariate analysis, ABI
at six months was on average 0.04 higher for the atorvastatin
group compared to the control group (adjusted for baseline FMD
and age), this difference being not significant (p=0.28).
Twelve patients in the control group and eight patients in the
atorvastatin group (23% vs. 16.6%, p=0.42) developed a drop in
ABI by at least 0.1 with or without worsening of clinical symp-
toms. Of these, nine patients in the control group and eight in the
atorvastatin group underwent revascularization procedures.
Laboratory findings
At six months` follow-up, total cholesterol, LDL-cholesterol and
triglycerides were lower in the atorvastatin group than in the con-
trol group (Table 2). No differences were seen in CRP, D-dimer,
fibrinogen and lipoprotein a between the two groups.
Further, there were also no differences between baseline
values and values at six months in CRP, D-dimer, fibrinogen and
lipoprotein a in either group (all p>0.05).
Figure 2: Flow-mediated dilation (FMD)
at baseline and at six months by groups.
Boxes show medians (25
th
to 75
th
percentile);
the grey dots represent all observations <10
th
or > 90
th
percentile, respectively.
Figure 3: Intima-media thickness (IMT).
A) IMT at baseline and at 6 months by
groups.Boxes show medians (25
th
to 75
th
per-
centile); the grey dots represent all observa-
tions <10
th
or > 90
th
percentile, respectively. B)
Patients with and without progression of inti-
ma-media thickness (IMT), expressed as %
change from baseline, by groups. Boxes show
medians (25
th
to 75
th
percentile); the blue dots
represent all observations <10
th
or > 90
th
per-
centile, respectively.
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MACE
Myocardial infarction occurred in one patient in the atorvastatin
group and in one patient in the control group (2.1 vs. 1.9%,
p= 0.61). There were no strokes and no vascular deaths in either
group.
Discussion
In this open, randomized controlled trial aggressive lipid-lower-
ing with atorvastatin 80 mg daily for six months had no effect on
brachial artery endothelial function in patients with PAD.
Atorvastatin is known as a potent drug for lipid-lowering ther-
apy with many pleiotropic properties. One of these properties is a
protective effect on endothelial function. Data in recent studies
have shown that therapy with statins may improve endothelial dys-
function both in patients with type 1 diabetes (24) and in patients
with familial hypercholesterolemia (25). Treatment with 80 mg of
atorvastatin in healthy smokers with normal cholesterol levels
normalized endothelial function after four weeks (26). As data on
high-dose atorvastatin treatment in PAD patients are not available
so far, the aim of our study was to investigate the effect of such a
therapy on FMD in this high-risk patients in a randomized con-
trolled setting.Our finding that we did not observe a significant ef-
fect of high-dose atorvastatin on FMD in our PAD patients is in
contrast to findings of the effects of high-dose atorvastatin in other
patient cohorts. Several potential reasons for the negative findings
in our study have to be addressed: First, patients referred to a ter-
tiary center might represent a negative selection with more ad-
vanced (generalized) disease; of all patients included in our study,
80% had a history of a peripheral revascularization procedure (in-
terventional procedure and/or peripheral vascular surgery), a per-
centage which is extremely high (in contrast, in the Heart Protec-
tion Study, only 40% of the PAD patients had a previous revascu-
larization procedure (27).The severity of the disease might also be
reflected by the low baseline values of FMD (3–4%), which have
been shown to be associated with an adverse outcome (16).Data of
the ASAP study (28) suggest a strong effect of atorvastatin on en-
dothelial function at an early stage, whereas at later stages of prog-
ressed atherosclerosis, which was the clinical situation in our pa-
tients, effects might be much less obvious. Furthermore, it has to
be pointed out that 96% of the patients in our control group were
on low-dose statins as part of standard medical treatment, making
it much more difficult to detect presumed effects in the treatment
group. Finally, nearly one third of the patients in our treatment
group were diabetics. It is known that intensive lipid-lowering by
80 mg atorvastatin is unable to restore endothelial function in type
2 diabetic patients (29).
An important and crucial mechanism by which statins exert
their pleiotropic effects is the upregulation of endothelial nitric
oxide synthase (eNOS) (30), increased NO bioavailability (31),
and prevention of NO scavenging by reactive oxygen species
(ROS) (32). It is well known that advanced stages of athero-
sclerosis are associated with an increased production of free rad-
icals, and that an excess production of the ROS will scavenge and
hence inactivate NO. The positive effect of statins exerted via the
eNOS pathway will then, at least partly, be blunted.
IMT of the common carotid artery and the ABI after six
months treatment were not different between patients receiving
high-dose atorvastatin compared with controls receiving con-
ventional medical therapy. In theASAP study Smilde et al. could
demonstrate a significant reduction of IMT of the carotid artery
in patients with heterozygous familial hypercholesterolemia
after two years’ treatment with high-dose atorvastatin (80 mg per
day) (28). Furthermore, data of the ARBITER study showed a
significant regression of IMT of the carotid artery after more
Figure 4: Ankle-brachial index (ABI) at
baseline and at six months by groups.
Boxes show medians (25
th
to 75
th
percentile);
the blue dots represent all observations <10
th
or > 90
th
percentile, respectively.
Table 2: Laboratory values at six months by treatment group.
Atorvastatin
(n=48)
Control (n=51) P
Total cholesterol, mM 003.85 (3.40–4.35) 004.50 (3.92–5.10) 0.0006
LDL cholesterol, mM 001.86 (1.38–2.29) 002.33 (1.82–2.85) 0.0028
HDL cholesterol, mM 001.25 (1.10–1.49) 001.23 (0.96–1.41) 0.28
Triglycerides, mM 001.43 (1.07–1.93) 002.01 (1.47–2.47) 0.0097
Blood glucose, mM 005.60 (4.97–7.20) 005.80 (5.07–8.05) 0.35
Lipoprotein a, mg/l 135 (44–285) 148 (40.7–667.3) 0.51
C-reactive protein, mg/l 002.20 (1.15–5.35) 003.00 (1.62–6.55) 0.23
Fibrinogen, mg/dl 350 (311.25–410) 360 (315–397.50) 0.96
D-dimer, mg/l 000.20 (0.20–0.40) 000.30 (0.20–0.47) 0.21
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than two years of treatment with atorvastatin 80 mg per day (33).
However, in both studies particulary patients with coronary heart
disease only, not PAD, were included.
In our study follow-up was only six months. This might have
been a potential reason why we were unable to observe an effect
of high-dose atorvastatin therapy on IMT. On the other hand,
however, in contrast to our results, a previous pilot study showed
a significant reduction in carotid IMT already after eight weeks
of treatment with only 20 mg atorvastatin/day in patients with
PAD (9). Our data on high-dose atorvastatin treatment in patients
with PAD will add to the controversy of the potential additional
benefit of intensive lipid-lowering treatment with atorvastatin on
the progression of coronary atherosclerosis as elucidated by a re-
cent multicenter trial (34). From our current data, a certain new
controversy may arise with respect to the effects of high-dose
atorvastatin in patients with PAD.
At first glance, our results are contradictory to those of two
recently published large trials demonstrating improved outcome
and reduced peripheral vascular events in PAD patients using
statins (27, 35). Data from the Heart Protection Study about the
benefits of cholesterol-lowering with statin therapy in patients
with PAD revealed that medication with 40 mg simvastatin daily
reduced vascular events both in participants with PAD and in
those without pre-existing PAD (27). Unlike this study, which
was only done retrospectively, we used a daily 80 mg dose of
atorvastatin in a randomized setting. Feringa et al. (35) prospec-
tively studied in a not randomized trial more than 1,300 patients
with PAD. In this study, statin dosage was not fixed but adjusted
and converted to a percentage value of maximum recommended
therapeutic dose. To the best of our knowledge, our study is the
only prospectively randomized controlled trial investigating the
effects of high-dose atorvastation in patients with PAD. Al-
though we recorded and reported MACE in our trial, these were,
unlike those trials, not an endpoint in our study. Therefore, we
definitely do not want to conclude from our data that high-dose
atorvastatin may not be clinically beneficial in PAD patients, as
our study was not designed to answer this question. We are aware
of the fact that our results cannot challenge the data from the two
mentioned large scale clinical trials.
In our investigation, we were also unable to show any effect
of atorvastatin 80 mg/day on CRP and fibrinogen. Indeed, in
clinical trials in patients with coronary artery disease, aggressive
lipid-lowering with atorvastatin diminished CRP (36, 37). In the
study performed by Ridker on patients with acute coronary syn-
dromes, baseline median CRP was 2 mg/l (8). The rather high
levels of CRP in our patients (atorvastatin 80 mg group: 3 mg/l
vs. control group: 3.4 mg/l) suggest an advanced stage of athero-
sclerosis present in the majority of our patients. Fibrinogen was
reported to be reduced in patients with coronary artery disease
when atorvastatin (10 mg/day) was given for three months only
(38). Interestingly, atorvastatin at doses between 10 to 40 mg/day
was recently shown to diminish soluble Fas, a circulating marker
of inflammation secreted by cells implicated in atherosclerotic
lesions, whereas atorvastatin 80 mg/ day had no significant ef-
fect on sFas reduction (39). Therefore, it is conceivable that the
effects of atorvastatin on inflammatory markers may be dose-de-
pendently modifiable.
Taken together, we failed to demonstrate an effect of atorvas-
tatin 80 mg per day on FMD in PAD patients at six months. How-
ever, this does not mean that high-dose atorvastatin might not re-
duce the risk of vascular events in this time interval, as our study
was not designed to answer this question. The impact of a high-
dose regimen on the pleiotropic effects will particularly be
needed to be clarified in the future. Certainly, more profound
mechanistic insights into the complex relationship between
lipid-lowering therapy, atherosclerosis and plaque burden are
still needed.
Study limitations
The following limitations have to be addressed: the study was not
blinded, and statin treatment in the control group was not stan-
dardized. A large, randomized, double-blind study comparing
high-dose atorvastatin with a standard dose group would be
needed to clarify whether intense atorvastatin is superior in PAD
patients with respect to clinical endpoints.
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